@article{8f21abf340024d20a1b9adcb42aa73d8,
title = "Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists",
abstract = "Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in coronavirus disease 2019 (COVID-19) are scarce. This article reviews and offers guidance based on currently available safety data and the most recent COVID-19 outcome data in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasizes a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic.",
keywords = "COVID-19, SARS-CoV-2, autoimmune disease, dermatology-rheumatology, immunosuppression, immunosuppressive therapy, medical dermatology",
author = "{Zahedi Niaki}, Omid and Anadkat, {Milan J.} and Chen, {Steven T.} and Fox, {Lindy P.} and Joanna Harp and Micheletti, {Robert G.} and Nambudiri, {Vinod E.} and Pasieka, {Helena B.} and Shinohara, {Michi M.} and Misha Rosenbach and Merola, {Joseph F.}",
note = "Funding Information: Conflicts of interest: Dr Niaki has participated in an advisory board for Eli Lilly. Dr Anadkat is currently serving as consultant for Boehringer-Ingelheim, NovoCure, and OnQuality and as an investigator for Biogen, Lutris, AnaptyxBio, Boehringer-Ingelheim, OnQuality, Norvartis, ChemoCentryx, UCB Biopharma, and XBiotech. Dr Shinohara has been a principle investigator for clinical trials (Actelion, Soligenix, MiRAGEN). Dr Rosenbach, has served as a consultant for Merck, aTyr, Processa, and Janssen and has received research support from Processa and salary support from JAMA Dermatology. Dr Merola is a consultant and/or investigator for Merck, Bristol-Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Drs Chen, Fox, Harp, Micheletti, Nambudiri, and Pasieka have no conflicts of interest to declare. Funding sources: None. Publisher Copyright: {\textcopyright} 2020 American Academy of Dermatology, Inc.",
year = "2020",
month = oct,
doi = "10.1016/j.jaad.2020.06.051",
language = "English",
volume = "83",
pages = "1150--1159",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
number = "4",
}